Anxiety, Sleep, and Inflammation

Evidence Review

Anxiety: Preclinical and Clinical Evidence (Blessing et al., 2015)

The foundational review by Blessing and colleagues (PMID 26341731) synthesized evidence from both animal studies and human trials across anxiety disorder subtypes [1]. This was a comprehensive narrative review in Neurotherapeutics covering generalized anxiety disorder (GAD), social anxiety disorder (SAD), panic disorder, OCD, and PTSD.

Key findings from this review:

• Preclinical evidence was described as "strongly supportive" of CBD's anxiolytic effects, with consistent results across multiple animal models of anxiety
• Human imaging studies showed CBD reduced anxiety in response to public speaking in patients with social anxiety disorder, with corresponding decreases in activity in anxiety-related brain regions (parahippocampal gyrus, hippocampus, inferior temporal gyrus)
• CBD reduced anxiety induced by THC in healthy volunteers, and reduced experimentally-induced anxiety in non-clinical participants
• The authors noted that acute CBD administration consistently reduced anxiety in human trials, while evidence for chronic dosing was more limited at the time of writing

The review highlighted CBD's pharmacological advantage: unlike benzodiazepines, CBD does not appear to carry risks of dependence, tolerance development, or respiratory depression — a clinically meaningful distinction.

Anxiety and Sleep: Large Case Series (Shannon et al., 2019)

The retrospective case series by Shannon et al. (PMID 30624194) examined 72 adult patients who received CBD (primarily 25 mg/day in capsule form) in a clinical psychiatry setting, with the majority being treated for anxiety [2].

Results at one-month follow-up:

• Anxiety scores (measured via validated Hamilton Anxiety Rating Scale) improved in 79.2% of patients within the first month
• Sleep scores improved in 66.7% of patients within the first month
• Anxiety improvements were sustained over the full 3-month observation period
• Sleep improvements showed more variability month to month, suggesting anxiety benefits may be more durable than sleep benefits at this dose
• CBD was well tolerated; only 3 of 72 patients reported adverse effects (sedation in 2 patients, fatigue in 1)

Limitations: Retrospective, no control group, open-label design. However, the sample was clinically meaningful — these were real patients in a psychiatry practice rather than recruited volunteers — and the response rate was high.

Epilepsy: Phase 3 RCT (Devinsky et al., 2017)

The landmark trial by Devinsky and colleagues (PMID 28538134), published in the New England Journal of Medicine, was the pivotal study that led to FDA approval of pharmaceutical-grade CBD (Epidiolex) for treatment-resistant epilepsy [3].

Study design:

• 120 children and young adults with Dravet syndrome (a severe, drug-resistant form of childhood epilepsy)
• Double-blind, placebo-controlled trial
• CBD at 20 mg/kg/day for 14 weeks, added to existing antiepileptic medications

Results:

• Median convulsive seizure frequency dropped from 12.4 to 5.9 per month in the CBD group
• Compared to a decrease from 14.9 to 14.1 per month in the placebo group
• Adjusted median difference between groups: −22.8 percentage points (95% CI: −41.1 to −5.4; p = 0.01)
• 5% of CBD patients became seizure-free vs. 0% in the placebo group
• 43% of CBD-treated patients achieved ≥50% reduction in seizure frequency vs. 27% placebo
• Adverse events were more common in the CBD group, including diarrhea, vomiting, and elevated liver enzymes — notable when CBD is co-administered with valproate

This trial directly resulted in the 2018 FDA approval of Epidiolex — the first plant-derived, pharmaceutical-grade cannabinoid approved in the US, and the first CBD-based medicine with proven efficacy in a rigorous RCT.

Anti-Inflammatory and Antioxidant Properties (Iffland & Grotenhermen, 2020)

The comprehensive review by Iffland and Grotenhermen (PMID 31881765) synthesized preclinical and early clinical evidence for CBD's antioxidant and anti-inflammatory mechanisms [4].

Key findings:

• CBD demonstrated antioxidant effects by reducing lipid peroxidation and reactive oxygen species (ROS) in neuronal and liver cell models
• CBD inhibited NF-κB signaling — a central pathway in inflammatory gene activation — in multiple cell types
• CBD reduced TNF-alpha, IL-6, and IL-1beta release from activated macrophages and microglia
• In animal models of inflammatory conditions (colitis, neuropathic pain, arthritis), CBD consistently reduced inflammatory markers and pain behavior
• The review identified CBD's interaction with TRPV1 (transient receptor potential vanilloid 1) receptors as a mechanism for pain modulation — these are the same receptors targeted by capsaicin

The authors noted that CBD's multi-target anti-inflammatory profile makes it particularly relevant for conditions driven by chronic, low-grade inflammation, though large clinical trials in human inflammatory conditions were at the time still limited.

Safety and Drug Interactions

CBD's safety profile in clinical studies is generally favorable at supplement-level doses (25–300 mg/day):

• Most common side effects: fatigue, diarrhea, changes in appetite — typically mild and dose-dependent
• Liver enzyme elevations have been observed at high pharmaceutical doses (20 mg/kg/day) used in epilepsy trials, particularly with concurrent valproate use; this is not typical at lower supplemental doses
• CBD inhibits several CYP450 liver enzymes (particularly CYP3A4 and CYP2C9), which can affect the metabolism of medications including warfarin, clobazam, and some statins — consultation with a prescriber is warranted for people on these medications
• No evidence of abuse potential, physical dependence, or withdrawal has been documented

Strength of Evidence Summary

Condition	Evidence Quality	Notes
Epilepsy (Dravet/LGS)	Strong — FDA-approved RCT	High doses; pharmaceutical grade required
Anxiety	Moderate — consistent but mostly small/open trials	Promising; larger RCTs ongoing
Sleep	Low-moderate — case series, pilot trials	Likely secondary to anxiety reduction
Inflammation/Pain	Preclinical strong; clinical early-stage	Mechanism well-characterized; RCTs limited

CBD is one of the better-characterized natural compounds in terms of mechanism of action and has cleared the highest regulatory bar (FDA approval) in one indication. For anxiety and sleep at typical supplement doses, the evidence is encouraging but clinical trial quality has historically been limited — this is an area where the research base is actively growing as regulatory and scheduling barriers to research ease.